Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients
- 1 December 2011
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 6 (12), 2018-2026
- https://doi.org/10.1097/jto.0b013e3182307e1f
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patientsAnnals of Oncology, 2006
- ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal CancerClinical Cancer Research, 2005
- Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer DrugsClinical Cancer Research, 2005
- Severe Drug Toxicity Associated with a Single-Nucleotide Polymorphism of the Cytidine Deaminase Gene in a Japanese Cancer Patient Treated with Gemcitabine plus CisplatinClinical Cancer Research, 2005
- Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevanceLung Cancer, 2005
- Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based ChemotherapyClinical Cancer Research, 2004
- XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non—Small-Cell Lung Cancer Patients Treated With Platinum ChemotherapyJournal of Clinical Oncology, 2004
- Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapyLung Cancer, 2004
- Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivoOncogene, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000